COOL LINE CATHETER KIT, MODELS CL-2085B, CL-2295A; ICY CATHETER KIT, MODEL IC-3585A; FORTIUS CATHETER KIT, MOD. FR-5093B
Device Facts
| Record ID | K051912 |
|---|---|
| Device Name | COOL LINE CATHETER KIT, MODELS CL-2085B, CL-2295A; ICY CATHETER KIT, MODEL IC-3585A; FORTIUS CATHETER KIT, MOD. FR-5093B |
| Applicant | Alsius Corp. |
| Product Code | NCX · Cardiovascular |
| Decision Date | Oct 11, 2005 |
| Decision | SESU |
| Submission Type | Traditional |
| Regulation | 21 CFR 870.5900 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The Alsius CoolGard® 3000 and Cool Line ™ Catheter Thermal Requlation System is indicated for use in fever reduction, as an adjunct to other antipyretic therapy, in patients with cerebral infarction and intracerebral hemorrhage who require access to the central venous circulation and who are intubated and sedated. The COOLGARD™ 3000/Alsius Catheter Thermal Regulation System, using either the Icy™ or Fortius™ model catheter, is indicated for use: in cardiac surgery patients to achieve and or maintain normothermia during surgery and recovery/intensive care, and to induce, maintain and reverse mild hypothermia in neurosurgery patients in surgery and recovery/intensive care.
Device Story
System consists of CoolGard 3000 console and heat exchange catheters (Cool Line, Icy, Fortius). Device circulates coolant through closed-loop catheter placed in central venous circulation to regulate patient core temperature. Used in OR, ICU, or recovery settings by clinicians. Provides thermal regulation for fever management, normothermia maintenance, or mild hypothermia induction. Console controls coolant flow/temperature based on patient temperature feedback. Benefits include precise temperature control for neuro-critical or surgical patients. This specific submission adds labeling for use in MRI environments.
Clinical Evidence
Clinical evidence provided via a randomized controlled trial of 296 patients across four cohorts (cerebral infarction, intracerebral hemorrhage, primary traumatic brain injury, subarachnoid hemorrhage). Mortality results reported for each cohort comparing Cool Line to control. Safety not demonstrated for fever reduction in subarachnoid hemorrhage or primary traumatic brain injury patients.
Technological Characteristics
Thermal regulation system using closed-loop heat exchange catheters. Console-based coolant circulation. Class II device (21 CFR 870.5900).
Indications for Use
Indicated for fever reduction in intubated/sedated patients with cerebral infarction or intracerebral hemorrhage; also indicated for cardiac surgery patients to achieve/maintain normothermia and neurosurgery patients to induce/maintain/reverse mild hypothermia. Contraindicated for fever reduction in patients with subarachnoid hemorrhage or primary traumatic brain injury.
Regulatory Classification
Identification
A thermal regulating system is an external system consisting of a device that is placed in contact with the patient and a temperature controller for the device. The system is used to regulate patient temperature.
Predicate Devices
Submission Summary (Full Text)
{0}------------------------------------------------
## 000 1 1 2005
K05/9/2
# 3 510(k) Summary
## 510(k) SUMMARY FOR ALSIUS CORPORTATION'S COOLGARD AND CATHETER THERMAL REGULATION SYSTEM
#### Submitter's Name, Address, Telephone Number, and Contact Person:
ALSIUS CORPORATION 15770 Laguna Canyon Road, Suite 150 Irvine, CA 92618
Contact: Ken Collins Phone: 949-453-0150 Fax: 949-453-0250 Email: kcollins@alsius.com
#### Name of Device:
The Alsius CoolGard And Catheter Thermal Regulation System.
#### Common or Usual Name:
Central Venous Catheter (short term) and Thermal Regulating System.
#### Classification Name:
FDA has classified the Alsius CoolGard/Catheter system for various indications as a Class II device under 21 C.F.R. § 870.5900.
Pg 1 of 3
{1}------------------------------------------------
### Indications for Use
### Cool Line Cathers - Indications for Use:
The Alsius CoolGard® 3000 and Cool Line ™ Catheter Thermal Requlation System is indicated for use in fever reduction, as an adjunct to other antipyretic therapy, in patients with cerebral infarction and intracerebral hemorrhage who require access to the central venous circulation and who are intubated and sedated.
### Warning - Fever Reduction
The safety of this device has not been demonstrated for fever reduction in patients presenting with subarrachnoid hemorrhage or primary traumatic brain injury. The safety and effectiveness of this device was examined in a randomized controlled trial of 296 patients. The mortality results reported in this trial, for the four patient cohorts enrolled, are presented in the table below (CI - cerebral infarction, ICH - intracerebral hemorrhage, PTBI - primary traumatic brain injury, SAH - subarrachnoid hemorrhage).
| | Cool Line | | | Control | | | |
|------|-----------|----|------|---------|----|------|------|
| | n | N | % | n | N | % | p* |
| CI | 3 | 16 | 18.8 | 3 | 14 | 21.4 | 0.74 |
| ICH | 8 | 33 | 24.2 | 7 | 27 | 25.9 | 1.00 |
| PTBI | 10 | 44 | 22.7 | 4 | 38 | 10.5 | 0.24 |
| SAH | 13 | 61 | 21.3 | 7 | 63 | 11.1 | 0.15 |
Mortality by Diagnosis (ITT analysis)
"Fischer's exact test
For more details on the clinical trial results please refer to Physician's Manual -"Normothermia for the Neuro-critically III stroke patient" #101416-001.
## Fortius and Icy Catheters - Indications for Use:
The COOLGARD™ 3000/Alsius Catheter Thermal Regulation System, using either the lcy™ or Fortius™ model catheter, is indicated for use:
- . in cardiac surgery patients to achieve and or maintain normothermia during surgery and recovery/intensive care, and
- . to induce, maintain and reverse mild hypothermia in neurosurgery patients in surgery and recovery/intensive care.
\$\frac{1}{7}\$ 2 of 3
{2}------------------------------------------------
## Summary of the Basis for Finding of Substantial Equivalence:
This submission relates to the addition of labeling relating to the use of the Alsius Cool Line®, Icy® and Fortius® Catheters in an MRI environment.
The predicate devices for this change in labeling are the catheters themselves as cleared under the following 510(k): K030421 (Fortius and ICY) and K014241 (Cool Line).
The labeling of these catheters is otherwise unchanged.
#### Conclusion
In summary, descriptive information and performance data demonstrate that the Alsius CoolGard and Catheter Thermal Regulation System characteristics do not raise new questions of safety and effectiveness. Where appropriate, performance data demonstrate equivalence. The CoolGard system is substantially equivalent to the predicate device.
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three curved lines representing its wings. The text "DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S." is arranged in a circular pattern around the eagle.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Kenneth A. Collins, M.D. Vice President Clinical/Quality/Regulatory Alsius Corporation 15770 Laguna Canyon, Road, Suite 150 Irvine, California 92618
Re: K051912
Trade/Device Name: Alsius Cool Line, Icy & Fortius Heat Exchange Catheters Regulation Number: 21 CFR 870.5900 Regulation Name: Thermal regulating system Regulatory Class: Class II Product Code: NCX Dated: September 20, 2005 Received: September 21, 2005
Dear Dr. Collins:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the gencral controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
The Office of Device Evaluation has determined that there is a reasonable likelihood that the Cool Line Catheter will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(L) of the Act, the following limitation must appear in the Warnings section of the device's labeling as a box warning immediately following the indications for use statement:
OCT 11 2005
{4}------------------------------------------------
Page 2 - Kenneth A. Collins, M.D.
The safety of this device has not been demonstrated for fever reduction in patients presenting with subarrachnoid hemorrhage or primary traumatic brain injury. The safety and effectiveness of this device was examined in a randomized controlled trial of 296 patients. The mortality results reported in this trial, for the four patient cohorts enrolled, are presented in the table below (CI - cerebral infarction, ICH - intracerebral hemorrhage, PTBI - primary traumatic brain injury, SAH - subarrachnoid hemorrhage).
| | Cool Line | | | Control | | | |
|------|-----------|----|------|---------|----|------|----------|
| | n | N | % | n | N | % | p-value* |
| CI | 3 | 16 | 18.8 | 3 | 14 | 21.4 | 0.74 |
| ICH | 8 | 33 | 24.2 | 7 | 27 | 25.9 | 1.00 |
| PTBI | 10 | 44 | 22.7 | 4 | 38 | 10.5 | 0.24 |
| SAH | 13 | 61 | 21.3 | 7 | 63 | 11.1 | 0.15 |
Mortality by Diagnosis (ITT)
*Fischer's exact test
For more details on the results of this study please refer to Physician's Manual - "Normothermia for the Neuro-critically III stroke patient" #101416-001.
Please note that the above labeling limitation is required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before this limitation is modified in any way or removed from the device's labeling. This limitation does not apply to the Icy & Fortius Catheters.
The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not I carted to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the clectronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{5}------------------------------------------------
Page 3 - Kenneth A. Collins, M.D.
If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International, and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Qeartul
Donna-Bea Tillman, Ph.D., M.P.A. Director Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{6}------------------------------------------------
## Indications for Use
510(k) Number (if known): Device Name:
K051912 CoolGard and Catheter Thermal Regulation System
Indications For Use:
#### Fortius and Icy Catheters - Indications for Use:
The COOLGARD™ 3000/Alsius Catheter Thermal Regulation System, using either the Icy™ or Fortius™ model catheter, is indicated for use:
- in cardiac surgery patients to achieve and or maintain normothermia during . surgery and recovery/intensive care, and
- to induce, maintain and reverse mild hypothermia in neurosurgery patients in . surgery and recovery/intensive care.
Prescription Use _X___________________________________________________________________________________________________________________________________________________________ (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | |
|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Page 2 of 2 | (Division Sign-Off) Division of General, Restorative, and Neurological Devices |
| Page 9 | 510(k) Number K051917 |
{7}------------------------------------------------
# Indications for Use
510(k) Number (if known):
Device Name:
K051912 CoolGard and Catheter Thermal Regulation System
Indications For Use:
#### Cool Line Cathers - Indications for Use:
The Alsius CoolGard® 3000 and Cool Line ™ Catheter Thermal Requlation System is indicated for use in fever reduction, as an adjunct to other antipyretic therapy, in patients with cerebral infarction and intracerebral hemorrhage who require access to the central venous circulation and who are intubated and sedated.
Warning - Fever Reduction
The safety of this device has not been demonstrated for fever reduction in patients presenting with subarrachnoid hemorrhage or primary traumatic brain injury. The safety and effectiveness of this device was examined in a randomized controlled trial of 296 patients. The mortality results reported in this trial, for the four patient cohorts enrolled, are presented in the table below (CI - cerebral infarction, ICH - intracerebral hemorrhage, PTBI - primary traumatic brain injury, SAH - subarrachnoid hemorrhage).
Mortality by Diagnosis (ITT analysis)
| | | Cool Line | | | Control | | | |
|------|----|-----------|------|---|---------|------|------|--|
| | n | N | % | n | N | % | p* | |
| CI | 3 | 16 | 18.8 | 3 | 14 | 21.4 | 0.74 | |
| ICH | 8 | 33 | 24.2 | 7 | 27 | 25.9 | 1.00 | |
| PTBI | 10 | 44 | 22.7 | 4 | 38 | 10.5 | 0.24 | |
| SAH | 13 | 61 | 21.3 | 7 | 63 | 11.1 | 0.15 | |
*Fischer's exact test
For more details on the clinical trial results please refer to Physician's Manual -"Normothermia for the Neuro-critically III stroke patient" #101416-001.
Prescription Use X
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(Part 21 CFR 801 Subpart D)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
evice Evaluation (ODE)
Mark A. Millussen
Page 1 of 2
(Division Sign-Division of General, Restorative, and Neurological Devices
Page 8
510(k) Number K051912
